Michael R. Verneris

Best Publications

• Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

  S. L. Maude;Theodore W Laetsch;J. Buechner;S. Rives

  5574
  Citations

• Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

  R Coleman Lindsley;Wael Saber;Brenton G Mar;Robert Redd

  799
  Citations

• Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C natural killer cells with potent function

  Bree Foley;Sarah Cooley;Michael R. Verneris;Michelle Pitt

  707
  Citations

• Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood

  Claudio G. Brunstein;Jonathan A. Gutman;Daniel J. Weisdorf;Ann E. Woolfrey

  583
  Citations

• Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

  Elena J. Orlando;Xia Han;Catherine Tribouley;Patricia A. Wood

  543
  Citations

• Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.

  Michael R. Verneris;Michael R. Verneris;Mobin Karami;Mobin Karami;Jeanette Baker;Jeanette Baker;Anishka Jayaswal;Anishka Jayaswal

  477
  Citations

• Clearance of Acute Myeloid Leukemia by Haploidentical Natural Killer Cells Is Improved Using IL-2 Diphtheria Toxin Fusion Protein

  Veronika Bachanova;Sarah Cooley;Todd E. Defor;Michael R. Verneris

  469
  Citations

• Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging

  Matthias Edinger;Yu An Cao;Michael R. Verneris;Michael H. Bachmann

  428
  Citations

• Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen

  Bree Foley;Sarah A Cooley;Michael R Verneris;Julie M Curtsinger

  424
  Citations

• Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect

  Claudio G. Brunstein;Jeffrey S. Miller;David H. McKenna;Keli L. Hippen

  415
  Citations

• First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

  Rizwan Romee;Sarah Cooley;Melissa M. Berrien-Elliott;Peter Westervelt

  411
  Citations

• Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

  Michelle K. Gleason;Todd R. Lenvik;Valarie McCullar;Martin Felices

  400
  Citations

• IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

  Daniel A. Vallera;Martin Felices;Ron McElmurry;Valarie McCullar

  372
  Citations

• Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT

  Jeffery S. Miller;Sarah Cooley;Peter Parham;Sherif S. Farag

  353
  Citations

• Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.

  Michael R. Verneris;Claudio G. Brunstein;Juliet Barker;Margaret L. MacMillan

  344
  Citations

• Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity.

  Petter S. Woll;Bartosz Grzywacz;Xinghui Tian;Rebecca K. Marcus

  304
  Citations

• Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production

  Jeanette Baker;Michael R. Verneris;Maki Ito;Judith A. Shizuru

  295
  Citations

• Advancing animal models of neoplasia through in vivo bioluminescence imaging.

  M. Edinger;Y.-a. Cao;Y.S. Hornig;D.E. Jenkins

  293
  Citations

• One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers

  John E. Wagner;Mary Eapen;Shelly Carter;Yanli Wang

  292
  Citations

• CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

  Michelle K. Gleason;Julie A. Ross;Erica D. Warlick;Troy C. Lund

  277
  Citations